Biopharma M&A Set for a Strong H2 Despite Political Noise—and Biogen and Gilead Look Like Buyers: Analysts
Mintz Member and Co-chair of the firm’s Life Sciences Practice William Whelan was quoted in an article published by Fierce Pharma discussing the findings of a Mintz / Mergermarket report, which provides insight into recent M&A activity and market views, as well as interesting comparatives to the previous year.
Source
FiercePharma